Multiple Myeloma

Selinexor has shown promising activity in very heavily pretreated patients with penta­refractory multiple myeloma. In the pivotal STORM Part 2 study, oral selinexor in combination with low-dose dexamethasone induced responses in 26.2% of patients. Read Article ›

Interim analysis of an international phase 3 clinical trial supports the addition of daratumumab (Darzalex) to lenalidomide (Revli­mid) and dexamethasone as the new standard of care in patients with newly diagnosed multiple myeloma who are transplant-ineligible. Read Article ›

The results of a phase 2 clinical trial presented at ASH 2018 suggest that early therapeutic intervention is beneficial in patients with high-risk smoldering multiple myeloma. Read Article ›



On February 12, 2019, the US Food and Drug Administration (FDA) granted approval for daratumumab (Darzalex; Janssen), a CD38-directed antibody, to be given in a split-dosing regimen to patients with multiple myeloma (MM). Read Article ›


Despite major advances in treatment interventions, multiple myeloma remains incurable in the majority of patients, and relapse is an expected part of the disease course. At the 2017 NCCN Hematologic Malignancies Congress, Natalie S. Callander, MD, a hematologist at the University of Wisconsin Carbone Cancer Center, Madison, outlined issues in the management of relapsed or refractory multiple myeloma. Read Article ›


Recent advances in the treatment of patients with multiple myeloma have dramatically altered the trajectory of the disease, as providers now have several efficacious agents in various drug classes at their disposal. At the 2017 NCCN Hematologic Malignancies Congress, Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic, Rochester, MN, provided management strategies for newly diagnosed multiple myeloma, including the role of autologous stem-cell transplant (ASCT) and posttransplant maintenance therapy. Read Article ›

Page 1 of 2

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: